SJS Investment Consulting’s Haemonetics HAE Stock Holding History

SJS Investment Consulting’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.3K	Sell	257 -47	-15%	-$3.02K	﹤0.01%	809
2026 Q1	$17.1K	Buy	304 +49	+19%	+$3.19K	﹤0.01%	706
2025 Q4	$20.4K	Buy	+255	New	+$17.1K	﹤0.01%	623
2025 Q3	–	Sell	-5	Closed	-$374	–	1666
2025 Q2	$374	Sell	5 -3	-38%	-$199	﹤0.01%	1207
2025 Q1	$509	Buy	8 +1	+14%	+$68	﹤0.01%	1245
2024 Q4	$547	Sell	7 -3	-30%	-$241	﹤0.01%	1210
2024 Q3	$805	Sell	10 -3	-23%	-$242	﹤0.01%	1141
2024 Q2	$1.08K	Hold	13	–	–	﹤0.01%	1003
2024 Q1	$1.11K	Hold	13	–	–	﹤0.01%	999
2023 Q4	$1.11K	Sell	13 -2	-13%	-$173	﹤0.01%	912
2023 Q3	$1.34K	Buy	15 +2	+15%	+$179	﹤0.01%	803
2023 Q2	$1.11K	Buy	13 +2	+18%	+$169	﹤0.01%	857
2023 Q1	$911	Sell	11 -3	-21%	-$243	﹤0.01%	931
2022 Q4	$1.1K	Buy	14 +3	+27%	+$241	﹤0.01%	896
2022 Q3	$1K	Buy	+11	New	+$790	﹤0.01%	747
2022 Q1	$0	Buy	+1	New	+$54	﹤0.01%	962

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's HAE Position: Q2 2026 in Review

SJS Investment Consulting reduced its Haemonetics (HAE) stake by 15% in Q2 2026, selling an estimated $3.02K and leaving 257 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #809.

SJS Investment Consulting first reported a position in HAE in Q1 2022 and has held it in 16 quarters since. The position peaked at $20.4K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

SJS Investment Consulting held 257 shares of Haemonetics worth $19.3K as of Q2 2026.
SJS Investment Consulting sold 47 Haemonetics shares in Q2 2026, an estimated $3.02K.
Haemonetics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #809 holding.
SJS Investment Consulting first reported a position in Haemonetics in Q1 2022 and has held it in 16 quarters since.
SJS Investment Consulting's Haemonetics position peaked at $20.4K in Q4 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.